Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: Studies in hypercholesterolemic and hypertensive patients

Journal of Cardiovascular Pharmacology

Volumn 40, Issue 1, 2002, Pages 28-34

  Hussein, Osamah ^a   Shneider, Julia ^a   Rosenblat, Mira ^a   Aviram, Michael ^a  

^a Rebecca Sieff Government Hospital   (Israel)

Author keywords

Fluvastatin; Hypercholesterolemia; Hypertension; Lipid peroxidation; Low density lipoprotein; Valsartan

Indexed keywords

CHOLESTEROL; COPPER ION; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VALSARTAN; ANTIOXIDANT; DRUG DERIVATIVE; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; TETRAZOLE DERIVATIVE; VALINE;

ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; METABOLISM; OXIDATION REDUCTION REACTION;

ANALYSIS OF VARIANCE; ANTIOXIDANTS; COMPARATIVE STUDY; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDOLES; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; TETRAZOLES; VALINE; HUMANS;

EID: 0035985466     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200207000-00004     Document Type: Article

References (37)

1. Beyond cholesterol: Modification of LDL that increases its atherogenicity
2. Atherosclerosis
3. Role of oxidized low-density lipoprotein in atherogenesis
4. Modified forms of LDL and atherosclerosis
5. Interaction of Ox-LDL with macrophages in atherosclerosis and the antiatherogenicity of antioxidants
6. Low density lipoprotein oxidation and its pathobiological significance
7. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man
8. Lesion low-density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated
9. Circulating oxidized low-density lipoprotein levels a biochemical risk marker for coronary heart disease
10. Brown MS Regulation of low-density lipoprotein receptors: Implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis
11. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients
12. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
13. Effect of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins
14. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy
15. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies
16. Simvastatin inhibits the oxidation of low-density lipoprotein by activated human monocyte derived macrophages
17. Hypolipidemic drug therapy reduces lipoprotein susceptibility to undergo lipid peroxidation: In vitro and ex vivo studies
18. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
19. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolemia
20. Reduced susceptibility of low density lipoprotein to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL
21. Antioxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contributes to prevention of atherosclerosis in cholesterol-fed rabbits
22. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro
23. Fluvastatin, an inhibitor of HMG-COA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver
24. Angiotensin, LDL peroxidation and atherosclerosis
25. LDL isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: A possible role for angiotensin II
26. Angiotensin II stimulates macrophage-mediated oxidation of low-density lipoproteins
27. Circulating versus local renin-angiotensin system in cardiovascular homeostasis
28. The angiotensin II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E deficient mice
29. The angiotensin converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice
30. Effect of valsartan and 17 Β-estradiol on the oxidation of low-density lipoprotein in vitro
31. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Application to mammalian blood and other tissues
32. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients
33. Protein measurement with the folin phenol reagent
34. Continuous monitoring of in vitro oxidation of human low-density lipoprotein
35. Microsomal lipid peroxidation
36. Pharmacokinetics of fluvastatin after single dose and multiple doses in normal volunteers
37. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia